Capital Cube • 14 days ago
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives ChemoCentryx, Inc. a score of 25. Our analysis is based on comparing ChemoCentryx, Inc. with the following peers – Fortress Biotech, Inc., Biogen Inc., Johnson & Johnson, AbbVie, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Amgen Inc., Pfizer Inc. and ... Read more (Read more...)
Capital Cube • 15 days agoChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : January 2, 2017
Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for ChemoCentryx, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
Benzinga • 25 days ago
ChemoCentryx Inc (NASDAQ: CCXI ) has expanded its kidney health partnership with Vifor Pharma to include the development and commercialization of CCX140 for renal diseases. CCX140 has previously completed ...
Insider Monkey • last month
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Capital Cube • 7 months ago
Click here to see latest analysisChemoCentryx, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -15.24 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.CCXI-US‘s earnings and EBITDA are both […] (Read more...) The post ChemoCentryx, Inc. :CCXI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 appeared first on CapitalCube.
Market Realist • 8 months ago
The Markets remained flat for the week ending May 13, 2016, with the SPDR S&P 500 ETF (SPY) falling marginally by 0.5%.
CCXI : Summary for ChemoCentryx, Inc. - Yahoo Finance
ChemoCentryx, Inc. (CCXI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Day's Range||7.91 - 8.26|
|52 Week Range||1.92 - 9.10|
|PE Ratio (TTM)||-8.24|
|Earnings Date||Mar 13, 2017 - Mar 17, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|